Actelion kept at neutral by Merrill

Merrill Lynch analyst Erica Whittaker retained Actelion at a neutral rating after a new positive analysis of the clazosentan phase 2 study was presented. Clazosentan is being developed to prevent vasospasm following subarachnoid hemorrhage. Actelion previously announced that while the study had met the primary endpoint of reducing angiographic vasospasm, there was no improvement detected in death, disability or other clinical outcomes. The latest data analysis showed a high variability in individual investigator-based assessments and a trend toward improvement in death and disability. Shares of the Allschwil, Switzerland-based pharmaceutical company were up CHF 2.80, or 1.55%, at CHF 183.70. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.